Indonesia Antiepileptics Drugs Market Report 2022 to 2030

Indonesia Antiepileptics Drugs Market Analysis

$ 3999

Indonesia Antiepileptics Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Epilepsy is a chronic neurological disorder characterized by recurrent seizures. The market for antiepileptic drugs is driven by the growing prevalence of epilepsy worldwide and the continuous need for effective and well-tolerated medications. Continuous advances in drug research and development help to bring new and improved antiepileptic treatments to market. These developments result in the creation of pharmaceuticals with improved efficacy, safety profiles, and fewer side effects, which drives market expansion. Some prominent players in the market include UCB Pharma, GlaxoSmithKline plc, Pfizer Inc., Novartis AG, Johnson & Johnson, Sanofi S.A., Eisai Co., Ltd., Sunovion Pharmaceuticals Inc., Cephalon, Inc., and Teva Pharmaceutical Industries Ltd.

ID: IN10IDPH238 CATEGORY: Pharmaceuticals GEOGRAPHY: Indonesia AUTHOR: Aneri Parekh

Buy Now

Indonesia Antiepileptics Drugs Market Analysis Summary

Indonesia Antiepileptics Drugs Market is valued at around $198.4 Mn in 2022 and is projected to reach $364.7 Mn by 2030, exhibiting a CAGR of 7.91% during the forecast period 2023-2030.

The pharmaceutical industry that focuses on the development, production, and distribution of medications used to treat epilepsy is referred to as the antiepileptic drugs market. Recurrent seizures characterize epilepsy, a persistent neurological condition. Antiepileptic medicines (AEDs) are medications that are used to assist manage and control seizures by reducing their frequency and intensity. These medications work by inhibiting the aberrant electrical activity in the brain that causes seizures. According to World Health Organization statistics for 2022, around 50 million people worldwide have epilepsy, making it the most well-known neurological illness globally.

The global prevalence of epilepsy and the ongoing need for effective and well-tolerated treatments drive the market for antiepileptic pharmaceuticals. Drug research and development advances, together with continued innovation, have resulted in the launch of new and improved AEDs with enhanced efficacy, safety profiles, and tolerability.

The market is crowded, with both generic and branded AEDs accessible. The market's major players invest in research and development to create new drugs and increase their product ranges. The antiepileptic drug industry is crucial in offering treatment alternatives for people with epilepsy, assisting them in achieving better seizure control and a higher quality of life. UCB UCB Pharma, GlaxoSmithKline plc, Pfizer Inc., Novartis AG, Johnson & Johnson, Sanofi S.A., Eisai Co., Ltd., Sunovion Pharmaceuticals Inc., Cephalon, Inc., and Teva Pharmaceutical Industries Ltd.

Market Dynamics

Market Growth Drivers

The rising global prevalence of epilepsy is a primary driver of the antiepileptic medication market. With an increasing number of people being diagnosed with epilepsy, there is a greater need for effective drugs to manage and control seizures. Continuous advances in drug research and development help to bring new and improved antiepileptic treatments to market. These developments result in the creation of pharmaceuticals with improved efficacy, safety profiles, and fewer side effects, which drives market expansion. Technological advances, such as the creation of targeted drug delivery methods and innovative drug formulations, improve the efficacy and usability of antiepileptic medication therapy. By increasing treatment outcomes and patient compliance, these innovations drive market expansion
The surge in healthcare spending by governments and individuals is boosting the antiepileptic medicines industry. Increased healthcare spending enables persons with epilepsy to have better access to medications, better treatment options, and a higher level of care. Increased epilepsy knowledge and enhanced diagnostic skills both contribute to higher diagnosis rates. As more people are diagnosed with epilepsy, there is an increase in demand for antiepileptic medications, which drives market expansion. Government activities aimed at improving epilepsy care and treatment, such as supporting research, launching awareness campaigns, and giving antiepileptic medicine subsidies or insurance coverage, operate as market drivers

Competitive Landscape

Key Players

UCB Pharma
GlaxoSmithKline plc
Pfizer Inc.
Novartis AG
Johnson & Johnson
Sanofi S.A.
Eisai Co., Ltd.
Sunovion Pharmaceuticals Inc.
Cephalon, Inc.
Teva Pharmaceutical Industries Ltd.

Development in Antiepileptics Drugs Market Analysis

Cerevel Therapeutics’ CVL-865 is under clinical study as adjunctive treatment in participants with drug-resistant focal onset seizures
Equilibre Biopharmaceuticals B.V. ‘s EQU-001 is under clinical trial study for the treatment of focal onset seizures in subjects aged 18 to 65 years. The study is estimated to be completed by October 2025

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Indonesia Antiepileptics Drugs Market Segmentation

By Seizure Type

Focal
Generalized
Non-Epileptic

By Drug Generation

First
Second
Third

By Route of Administration

Oral
IV
IM
Others

By Distribution Channel

Hospital and Clinics
Retail Pharmacy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.